{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T17:34:58Z","timestamp":1780421698811,"version":"3.54.1"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Shanghai Golden Leaf MedTech","award":["20231H03164"],"award-info":[{"award-number":["20231H03164"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Econ Rev"],"DOI":"10.1186\/s13561-025-00669-w","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T09:14:58Z","timestamp":1755076498000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Renal denervation for hypertension: cross-country cost-effectiveness insights from mainland China, Japan, and Thailand"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2650-9357","authenticated-orcid":false,"given":"Dai","family":"Lian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Suo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyan","family":"Gai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfeng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dunming","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingdong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6878-6272","authenticated-orcid":false,"given":"Shimeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3470-0748","authenticated-orcid":false,"given":"Yingyao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"issue":"10159","key":"669_CR1","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1016\/S0140-6736(18)32225-6","volume":"392","author":"GBD 2017 Risk Factor Collaborators","year":"2018","unstructured":"GBD 2017 Risk Factor Collaborators. Global, regional, and National comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1923\u201394.","journal-title":"Lancet"},{"issue":"10017","key":"669_CR2","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0140-6736(15)00805-3","volume":"387","author":"X Xie","year":"2016","unstructured":"Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, et al. Effects of intensive blood pressure Lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387(10017):435\u201343.","journal-title":"Lancet"},{"issue":"7","key":"669_CR3","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1001\/jamacardio.2017.1421","volume":"2","author":"JD Bundy","year":"2017","unstructured":"Bundy JD, Li C, Stuchlik P, Bu X, Kelly TN, Mills KT, et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network Meta-analysis. JAMA Cardiol. 2017;2(7):775\u201381.","journal-title":"JAMA Cardiol"},{"issue":"2","key":"669_CR4","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.2016.19043","volume":"317","author":"MH Forouzanfar","year":"2017","unstructured":"Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115\u00a0mm hg, 1990\u20132015. JAMA. 2017;317(2):165\u201382.","journal-title":"JAMA"},{"key":"669_CR5","unstructured":"World Health Organization. Global report on hypertension: the race against a silent killer 2023 [Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240081062"},{"issue":"10258","key":"669_CR6","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","volume":"396","author":"GBD 2019 Risk Factors Collaborators","year":"2020","unstructured":"GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1223\u201349.","journal-title":"Lancet"},{"issue":"12","key":"669_CR7","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1016\/j.jval.2023.09.429","volume":"26","author":"Y Tanaka","year":"2023","unstructured":"Tanaka Y, Yasuhara D, Yoshida H, Fleming C, Pietzsch J, Kario K. Healthcare expenditure for treatment of hypertension and hypertensive complications in Japan: a claims data analysis. Value Health. 2023;26(12):S81\u2013S.","journal-title":"Value Health"},{"key":"669_CR8","doi-asserted-by":"publisher","first-page":"1329768","DOI":"10.3389\/fpubh.2024.1329768","volume":"12","author":"HJ Hou","year":"2024","unstructured":"Hou HJ, Cong TZ, Cai Y, Ba YH, Chen ME, Yang JY, et al. Influencing factors of hospitalization cost of hypertension patients in traditional Chinese medicine hospitals. Front Public Health. 2024;12:1329768.","journal-title":"Front Public Health"},{"issue":"11","key":"669_CR9","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41569-021-00559-8","volume":"18","author":"B Zhou","year":"2021","unstructured":"Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol. 2021;18(11):785\u2013802.","journal-title":"Nat Rev Cardiol"},{"issue":"10199","key":"669_CR10","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/S0140-6736(19)31145-6","volume":"394","author":"NRF Collaboration","year":"2019","unstructured":"Collaboration NRF. Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. Lancet. 2019;394(10199):639\u201351.","journal-title":"Lancet"},{"key":"669_CR11","doi-asserted-by":"publisher","first-page":"e071952","DOI":"10.1136\/bmj-2022-071952","volume":"380","author":"M Zhang","year":"2023","unstructured":"Zhang M, Shi Y, Zhou B, Huang Z, Zhao Z, Li C, et al. Prevalence, awareness, treatment, and control of hypertension in china, 2004-18: findings from six rounds of a National survey. BMJ. 2023;380:e071952.","journal-title":"BMJ"},{"issue":"1","key":"669_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.2471\/BLT.13.121954","volume":"92","author":"N Ikeda","year":"2014","unstructured":"Ikeda N, Sapienza D, Guerrero R, Aekplakorn W, Naghavi M, Mokdad AH, et al. Control of hypertension with medication: a comparative analysis of National surveys in 20 countries. Bull World Health Organ. 2014;92(1):10\u2013c9.","journal-title":"Bull World Health Organ"},{"issue":"6","key":"669_CR13","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1161\/HYPERTENSIONAHA.109.138610","volume":"54","author":"MP Schlaich","year":"2009","unstructured":"Schlaich MP, Sobotka PA, Krum H, Whitbourn R, Walton A, Esler MD. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension. 2009;54(6):1195\u2013201.","journal-title":"Hypertension"},{"issue":"15","key":"669_CR14","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","volume":"370","author":"DL Bhatt","year":"2014","unstructured":"Bhatt DL, Kandzari DE, O\u2019Neill WW, D\u2019Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393\u2013401.","journal-title":"N Engl J Med"},{"issue":"23","key":"669_CR15","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1016\/j.jcin.2021.09.020","volume":"14","author":"Y Ahmad","year":"2021","unstructured":"Ahmad Y, Francis DP, Bhatt DL, Howard JP. Renal denervation for hypertension A systematic review and Meta-Analysis of randomized, blinded, Placebo-Controlled trials. JACC-Cardiovasc Interv. 2021;14(23):2614\u201324.","journal-title":"JACC-Cardiovasc Interv"},{"issue":"10137","key":"669_CR16","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/S0140-6736(18)31082-1","volume":"391","author":"M Azizi","year":"2018","unstructured":"Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391(10137):2335\u201345.","journal-title":"Lancet"},{"issue":"10234","key":"669_CR17","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/S0140-6736(20)30554-7","volume":"395","author":"M B\u00f6hm","year":"2020","unstructured":"B\u00f6hm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444\u201351.","journal-title":"Lancet"},{"key":"669_CR18","unstructured":"U.S. Food and Drug Administration. Premarket Approval: Paradise\u00ae Ultrasound Renal Denervation System 2023 [Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpma\/pma.cfm?id=P220023"},{"key":"669_CR19","unstructured":"U.S. Food and Drug Administration. Premarket Approval: Symplicity Spyral\u2122 Renal Denervation System 2023 [Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpma\/pma.cfm?id=P220026"},{"key":"669_CR20","unstructured":"China National Medical Products Administration. Approval of Renal Artery Radiofrequency Ablation Device and Single-Use Mesh Renal Artery Radiofrequency Ablation Catheter for Market Release 2024 [Available from: https:\/\/www.nmpa.gov.cn\/zhuanti\/cxylqx\/cxylqxlm\/20240806143621185.html"},{"key":"669_CR21","doi-asserted-by":"crossref","unstructured":"Li Y, Gao F, Ren C, Ma G, Bu P, Fu G et al. The Netrod six-electrode radiofrequency renal denervation system for uncontrolled hypertension: a sham-controlled trial. Eur Heart J. 2024;45(44):4761\u20134.","DOI":"10.1093\/eurheartj\/ehae703"},{"issue":"Suppl 1","key":"669_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/hec.3468","volume":"26","author":"R Tarricone","year":"2017","unstructured":"Tarricone R, Torbica A, Drummond M. Key recommendations from the MedtecHTA project. Health Econ. 2017;26(Suppl 1):145\u201352.","journal-title":"Health Econ"},{"issue":"6","key":"669_CR23","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/eurheartj\/ehs355","volume":"34","author":"M Dorenkamp","year":"2013","unstructured":"Dorenkamp M, Bonaventura K, Leber AW, Boldt J, Sohns C, Boldt L-H, et al. Potential lifetime cost-effectiveness of catheter-based renal sympathetic denervation in patients with resistant hypertension. Eur Heart J. 2013;34(6):451\u2013.","journal-title":"Eur Heart J"},{"issue":"14","key":"669_CR24","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.jacc.2012.07.029","volume":"60","author":"BP Geisler","year":"2012","unstructured":"Geisler BP, Egan BM, Cohen JT, Garner AM, Akehurst RL, Esler MD, et al. Cost-Effectiveness and clinical effectiveness of Catheter-Based renal denervation for resistant hypertension. J Am Coll Cardiol. 2012;60(14):1271\u20137.","journal-title":"J Am Coll Cardiol"},{"key":"669_CR25","doi-asserted-by":"crossref","unstructured":"Sharp ASP, Cao KN, Esler MD, Kandzari DE, Lobo MD, Schmieder RE, et al. Cost-effectiveness of catheter-based radiofrequency renal denervation for the treatment of uncontrolled hypertension: an analysis for the UK based on recent clinical evidence. European Heart Journal-Quality of Care and Clinical Outcomes; 2024.","DOI":"10.1093\/ehjqcco\/qcae001"},{"issue":"1","key":"669_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, De Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force. Value Health. 2022;25(1):10\u201331.","journal-title":"Value Health"},{"key":"669_CR27","unstructured":"World Bank. Data: Countries and Economies 2024 [Available from: https:\/\/data.worldbank.org\/country"},{"key":"669_CR28","unstructured":"Edejer TT-T. Making choices in health: WHO guide to cost-effectiveness analysis. World Health Organization; 2003."},{"key":"669_CR29","unstructured":"International Monetary Fund. GDP per capita, current prices 2023 [Available from: https:\/\/www.imf.org\/external\/datamapper\/NGDPDPC@WEO\/OEMDC\/ADVEC\/WEOWORLD\/JPN\/CHN\/THA"},{"key":"669_CR30","first-page":"299","volume-title":"China guidelines for Pharmacoeconomic evaluations","author":"G Liu","year":"2020","unstructured":"Liu G. China guidelines for Pharmacoeconomic evaluations. Beijing: China Market; 2020. p. 299."},{"issue":"SUPPL 5","key":"669_CR31","first-page":"S4","volume":"97","author":"U Chaikledkaew","year":"2014","unstructured":"Chaikledkaew U, Kittrongsiri K. Guidelines for health technology assessment in THailand (second edition)-the development process. J Med Assoc Thai. 2014;97(SUPPL 5):S4\u20139.","journal-title":"J Med Assoc Thai"},{"issue":"3","key":"669_CR32","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jval.2016.08.726","volume":"20","author":"T Shiroiwa","year":"2017","unstructured":"Shiroiwa T, Fukuda T, Ikeda S, Takura T, Moriwaki K. Development of an official guideline for the economic evaluation of drugs\/medical devices in Japan. Value Health. 2017;20(3):372\u20138.","journal-title":"Value Health"},{"issue":"12","key":"669_CR33","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s40273-022-01182-2","volume":"40","author":"X Dong","year":"2022","unstructured":"Dong X, He X, Wu J. Cost effectiveness of the First-in-Class ARNI (Sacubitril\/Valsartan) for the treatment of essential hypertension in a Chinese setting. PharmacoEconomics. 2022;40(12):1187\u2013205.","journal-title":"PharmacoEconomics"},{"key":"669_CR34","unstructured":"World Health Organization. World health statistics 2023: monitoring health for the SDGs, sustainable development goals 2023 [Available from: who.int\/publications\/i\/item\/9789240074323"},{"issue":"5","key":"669_CR35","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jacc.2022.11.038","volume":"81","author":"H Al Ghorani","year":"2023","unstructured":"Al Ghorani H, Kulenthiran S, Recktenwald MJM, Lauder L, Kunz M, Goetzinger F, et al. 10-Year outcomes of Catheter-Based renal denervation in patients with resistant hypertension. J Am Coll Cardiol. 2023;81(5):517\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"669_CR36","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1161\/HYPERTENSIONAHA.122.20853","volume":"80","author":"G Sesa-ashton","year":"2023","unstructured":"Sesa-ashton G, Nolde JM, Muente I, Carnagarin R, Lee R, Macefield VG, et al. Catheter-Based renal denervation: 9-Year Follow-Up data on safety and blood pressure reduction in patients with resistant hypertension. Hypertension. 2023;80(4):811\u20139.","journal-title":"Hypertension"},{"key":"669_CR37","unstructured":"Gao F, Zhou Y. Effectiveness and safety of the NetrodTM six-electrode radio frequency renal denervation system for the treatment of uncontrolled essential hypertension [Available from: https:\/\/www.pcronline.com\/Cases-resources-images\/Resources\/Course-videos-slides\/2023\/EuroPCR\/EuroPCR-2023-Hotlines-Late-Breaking-Trials-TAVI-hypertension-stroke-prevention]"},{"issue":"9","key":"669_CR38","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1161\/STROKEAHA.119.025553","volume":"50","author":"X Xing","year":"2019","unstructured":"Xing X, Yang X, Liu F, Li J, Chen J, Liu X, et al. Predicting 10-Year and lifetime stroke risk in Chinese population. Stroke. 2019;50(9):2371\u20138.","journal-title":"Stroke"},{"issue":"19","key":"669_CR39","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1161\/CIRCULATIONAHA.116.022367","volume":"134","author":"X Yang","year":"2016","unstructured":"Yang X, Li J, Hu D, Chen J, Li Y, Huang J, et al. Predicting the 10-Year risks of atherosclerotic cardiovascular disease in Chinese population: the China-PAR project (Prediction for ASCVD risk in China). Circulation. 2016;134(19):1430\u201340.","journal-title":"Circulation"},{"issue":"4","key":"669_CR40","first-page":"1223","volume":"6","author":"S-I Baek","year":"2012","unstructured":"Baek S-I, So W-Y. Waist circumference estimated on the basis of body mass index in Koreans. Healthmed. 2012;6(4):1223\u20136.","journal-title":"Healthmed"},{"issue":"5","key":"669_CR41","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1007\/s11427-018-9281-6","volume":"61","author":"C Han","year":"2018","unstructured":"Han C, Liu F, Yang X, Chen J, Li J, Cao J, et al. Ideal cardiovascular health and incidence of atherosclerotic cardiovascular disease among Chinese adults: the China-PAR project. Sci China Life Sci. 2018;61(5):504\u201314.","journal-title":"Sci China Life Sci"},{"key":"669_CR42","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ijcard.2017.05.086","volume":"248","author":"L Desta","year":"2017","unstructured":"Desta L, Jernberg T, Spaak J, Hofman-Bang C, Persson H. Risk and predictors of readmission for heart failure following a myocardial infarction between 2004 and 2013: A Swedish nationwide observational study. Int J Cardiol. 2017;248:221\u20136.","journal-title":"Int J Cardiol"},{"issue":"6","key":"669_CR43","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1161\/STROKEAHA.107.496752","volume":"39","author":"K Nakamura","year":"2008","unstructured":"Nakamura K, Barzi F, Lam TH, Huxley R, Feigin VL, Ueshima H, et al. Cigarette smoking, systolic blood pressure, and cardiovascular diseases in the Asia-Pacific region. Stroke. 2008;39(6):1694\u2013702.","journal-title":"Stroke"},{"issue":"6","key":"669_CR44","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1681\/ASN.2006111199","volume":"18","author":"K Reynolds","year":"2007","unstructured":"Reynolds K, Gu D, Muntner P, Kusek JW, Chen J, Wu X, et al. A population-based, prospective study of blood pressure and risk for end-stage renal disease in China. J Am Soc Nephrol. 2007;18(6):1928\u201335.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"669_CR45","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12882-017-0671-x","volume":"18","author":"EYF Wan","year":"2017","unstructured":"Wan EYF, Fong DYT, Fung CSC, Yu EYT, Chin WY, Chan AKC, et al. Prediction of new onset of end stage renal disease in Chinese patients with type 2 diabetes mellitus - a population-based retrospective cohort study. BMC Nephrol. 2017;18(1):257.","journal-title":"BMC Nephrol"},{"issue":"5","key":"669_CR46","doi-asserted-by":"publisher","first-page":"e12441","DOI":"10.1111\/1755-5922.12441","volume":"36","author":"Y Han","year":"2018","unstructured":"Han Y, Chen J, Qiu M, Li Y, Li J, Feng Y, et al. Predicting long-term ischemic events using routine clinical parameters in patients with coronary artery disease: the OPT-CAD risk score. Cardiovasc Ther. 2018;36(5):e12441.","journal-title":"Cardiovasc Ther"},{"issue":"S1","key":"669_CR47","first-page":"787","volume":"93","author":"H Wang","year":"2019","unstructured":"Wang H, Ning X, Zhu C, Yin D, Feng L, Xu B, et al. Prognostic significance of prior ischemic stroke in patients with coronary artery disease undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2019;93(S1):787\u201392.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"1","key":"669_CR48","doi-asserted-by":"publisher","first-page":"e0191155","DOI":"10.1371\/journal.pone.0191155","volume":"13","author":"YG Cherng","year":"2018","unstructured":"Cherng YG, Lin CS, Shih CC, Hsu YH, Yeh CC, Hu CJ, et al. Stroke risk and outcomes in patients with chronic kidney disease or end-stage renal disease: two nationwide studies. PLoS ONE. 2018;13(1):e0191155.","journal-title":"PLoS ONE"},{"issue":"13","key":"669_CR49","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296\u2013305.","journal-title":"N Engl J Med"},{"issue":"6","key":"669_CR50","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1053\/ajkd.2001.29219","volume":"38","author":"K Iseki","year":"2001","unstructured":"Iseki K, Wakugami K, Maehara A, Tozawa M, Muratani H, Fukiyama K. Evidence for high incidence of end-stage renal disease in patients after stroke and acute myocardial infarction at age 60 or younger. Am J Kidney Dis. 2001;38(6):1235\u20139.","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"669_CR51","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.cardfail.2017.09.014","volume":"23","author":"YH Zhang","year":"2017","unstructured":"Zhang YH, Zhang J, Butler J, Yang XM, Xie PY, Guo DS, et al. Contemporary epidemiology, management, and outcomes of patients hospitalized for heart failure in china: results from the China heart failure (China-HF) registry. J Card Fail. 2017;23(12):868\u201375.","journal-title":"J Card Fail"},{"issue":"3","key":"669_CR52","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1161\/CIRCOUTCOMES.109.910711","volume":"3","author":"A Moran","year":"2010","unstructured":"Moran A, Gu DF, Zhao D, Coxson P, Wang YC, Chen CS, et al. Future cardiovascular disease in China Markov model and risk factor scenario projections from the coronary heart disease policy model-China. Circulation-Cardiovascular Qual Outcomes. 2010;3(3):243\u201352.","journal-title":"Circulation-Cardiovascular Qual Outcomes"},{"key":"669_CR53","unstructured":"United States Renal Data System. 2022 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2022."},{"issue":"1","key":"669_CR54","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s12955-021-01879-6","volume":"19","author":"S Sang","year":"2021","unstructured":"Sang S, Kang N, Liao W, Wu X, Hu Z, Liu X, et al. The influencing factors of health-related quality of life among rural hypertensive individuals: a cross-sectional study. Health Qual Life Outcomes. 2021;19(1):244.","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"669_CR55","doi-asserted-by":"publisher","first-page":"e039653","DOI":"10.1136\/bmjopen-2020-039653","volume":"11","author":"F Yang","year":"2021","unstructured":"Yang F, Liao M, Wang P, Liu Y. Cost-effectiveness analysis of renal replacement therapy strategies in Guangzhou city, Southern China. BMJ Open. 2021;11(2):e039653.","journal-title":"BMJ Open"},{"issue":"4","key":"669_CR56","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jval.2016.11.016","volume":"20","author":"N Luo","year":"2017","unstructured":"Luo N, Liu G, Li M, Guan H, Jin X, Rand-Hendriksen K. Estimating an EQ-5D-5L value set for China. Value Health. 2017;20(4):662\u20139.","journal-title":"Value Health"},{"key":"669_CR57","unstructured":"Nation Bureau of Statistics. Statistical data 2024 [cited 2024 3.3]. Available from: https:\/\/data.stats.gov.cn\/easyquery.htm?cn=E0103"},{"key":"669_CR58","unstructured":"Statistics Bureau of Japan. Consumer Price Index 2024 [Available from: https:\/\/www.stat.go.jp\/english\/data\/cpi\/index.html"},{"key":"669_CR59","unstructured":"Bureau of Trade and Economic Indices. Report for Consumer Price Index of THAILAND 2024 [Available from: https:\/\/www.price.moc.go.th\/price\/cpi\/index.htm"},{"key":"669_CR60","unstructured":"International Monetary Fund. IMF Exchange Rates Report. 2023 [Available from: imf.org\/external\/np\/fin\/ert\/GUI\/Pages\/CountryDataBase.aspx"},{"key":"669_CR61","unstructured":"Shanghai Municipal Development & Reform Commission. 2023 Shanghai Municipal Price Information Guide for Residents 2023 [Available from: https:\/\/www.shanghai.gov.cn\/nw17239\/20240229\/1fcafdb2cfd14f1694d804a4bd0bf2ae.html"},{"key":"669_CR62","unstructured":"Ministry of Health Labour and Welfare. Medical Service Price List 2023 [Available from: https:\/\/www.mhlw.go.jp\/content\/12404000\/000907834.pdf"},{"issue":"7","key":"669_CR63","doi-asserted-by":"publisher","first-page":"A520","DOI":"10.1016\/S1098-3015(11)73147-3","volume":"13","author":"P Khonputsa","year":"2010","unstructured":"Khonputsa P, Veerman JL, Bertram M, Vos T, Generalized cost-effectiveness analysis, of pharmaceutical interventions for primary prevention of cardiovascular disease in thailand. Value Health. 2010;13(7):A520\u2013A.","journal-title":"Value Health"},{"key":"669_CR64","unstructured":"World Bank. International Comparison Program 2017 2024 [Available from: https:\/\/databank.worldbank.org\/source\/icp-2017"},{"key":"669_CR65","unstructured":"Yaozh.com. Bidding Price Database 2024 [Available from: https:\/\/www.yaozh.com\/"},{"key":"669_CR66","unstructured":"Drug And Medical Supply Information Center Ministry of Public Health. Medium price 2024 [Available from: https:\/\/dmsic.moph.go.th\/index\/drugsearch\/3"},{"key":"669_CR67","unstructured":"Kegg KEGGDRUG, Database. 2024 [Available from: https:\/\/www.kegg.jp\/medicus-bin\/japic_med?japic_code=00043804"},{"key":"669_CR68","unstructured":"Liu L-S, Joint Comm Guideline R. 2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. Journal of Geriatric Cardiology. 2019;16(3):182-+."},{"issue":"12","key":"669_CR69","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.31557\/APJCP.2023.24.12.4117","volume":"24","author":"P Laopachee","year":"2023","unstructured":"Laopachee P, Siripongsakun S, Sangmala P, Chanree P, Hiranrat P, Srisittimongkon S. Cost-Effectiveness analysis of ultrasound surveillance for cholangiocarcinoma in an endemic area of Thailand. Asian Pac J Cancer Prevention: APJCP. 2023;24(12):4117\u201325.","journal-title":"Asian Pac J Cancer Prevention: APJCP"},{"key":"669_CR70","unstructured":"All Japan Hospital Association. Medical expense 2024 [Available from: https:\/\/www.ajha.or.jp\/hms\/qualityhealthcare\/indicator\/09\/"},{"issue":"10","key":"669_CR71","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1016\/j.clinthera.2019.07.016","volume":"41","author":"K Kaku","year":"2019","unstructured":"Kaku K, Haneda M, Sakamaki H, Yasui A, Murata T, Ustyugova A, et al. Cost-effectiveness analysis of empagliflozin in Japan based on results from the Asian subpopulation in the EMPA-REG OUTCOME trial. Clin Ther. 2019;41(10):2021\u201340.","journal-title":"Clin Ther"},{"issue":"10","key":"669_CR72","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s40273-019-00820-6","volume":"37","author":"K Kongpakwattana","year":"2019","unstructured":"Kongpakwattana K, Ademi Z, Chaiyasothi T, Nathisuwan S, Zomer E, Liew D, et al. Cost-Effectiveness analysis of Non-Statin Lipid-Modifying agents for secondary cardiovascular disease prevention among Statin-Treated patients in Thailand. PharmacoEconomics. 2019;37(10):1277\u201386.","journal-title":"PharmacoEconomics"},{"issue":"5","key":"669_CR73","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40256-018-0288-x","volume":"18","author":"R Krittayaphong","year":"2018","unstructured":"Krittayaphong R, Permsuwan U. Cost-Effectiveness analysis of Sacubitril-Valsartan compared with Enalapril in patients with heart failure with reduced ejection fraction in Thailand. Am J Cardiovasc Drugs. 2018;18(5):405\u201313.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"1","key":"669_CR74","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1080\/13696998.2023.2266275","volume":"26","author":"I Kamae","year":"2023","unstructured":"Kamae I, Zhong Y, Hara H, Inoue K, Yasaka M, Reddy VY, et al. Cost-effectiveness of left atrial appendage closure with watchman for non-valvular atrial fibrillation patients in Japan. J Med Econ. 2023;26(1):1357\u201367.","journal-title":"J Med Econ"},{"key":"669_CR75","doi-asserted-by":"crossref","unstructured":"Boettiger DC, Newall AT, Chattranukulchai P, Chaiwarith R, Khusuwan S, Avihingsanon A et al. Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in thailand: a cost-effectiveness analysis. J Int AIDS Soc. 2020;23.","DOI":"10.1002\/jia2.25494"},{"issue":"11","key":"669_CR76","first-page":"78","volume":"23","author":"L Liu","year":"2022","unstructured":"Liu L, Ding Q, Zhang J. Influencing factors of hospitalization expenses for End-stage renal disease Hemodialysis patients in a tertiary public hospital. Chin Med Record. 2022;23(11):78\u201381.","journal-title":"Chin Med Record"},{"issue":"2","key":"669_CR77","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10157-011-0567-1","volume":"16","author":"M Kondo","year":"2012","unstructured":"Kondo M, Yamagata K, Hoshi S-L, Saito C, Asahi K, Moriyama T, et al. Cost-effectiveness of chronic kidney disease mass screening test in Japan. Clin Exp Nephrol. 2012;16(2):279\u201391.","journal-title":"Clin Exp Nephrol"},{"issue":"12","key":"669_CR78","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1253\/circj.CJ-22-0086","volume":"86","author":"S Kodera","year":"2022","unstructured":"Kodera S, Morita H, Nishi H, Takeda N, Ando J, Komuro I. Cost-Effectiveness of Dapagliflozin for chronic kidney disease in Japan. Circ J. 2022;86(12):2021\u2013.","journal-title":"Circ J"},{"key":"669_CR79","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.vhri.2019.10.004","volume":"21","author":"T Thaweethamcharoen","year":"2020","unstructured":"Thaweethamcharoen T, Sritippayawan S, Noparatayaporn P, Aiyasanon N. Cost-Utility analysis of continuous ambulatory peritoneal Dialysis and automated peritoneal Dialysis for Thai patients with End-Stage renal disease. Value Health Reg Issues. 2020;21:181\u20137.","journal-title":"Value Health Reg Issues"},{"issue":"5","key":"669_CR80","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1053\/j.ajkd.2019.08.005","volume":"75","author":"SCW Tang","year":"2020","unstructured":"Tang SCW, Yu X, Chen HC, Kashihara N, Park HC, Liew A, et al. Dialysis care and Dialysis funding in Asia. Am J Kidney Dis. 2020;75(5):772\u201381.","journal-title":"Am J Kidney Dis"},{"key":"669_CR81","doi-asserted-by":"crossref","unstructured":"Zhang H, Zhang C, Zhu S, Ye H, Zhang D. Direct medical costs of end-stage kidney disease and renal replacement therapy: a cohort study in Guangzhou city, Southern China. BMC Health Serv Res. 2020;20(1).","DOI":"10.1186\/s12913-020-4960-x"},{"key":"669_CR82","doi-asserted-by":"crossref","unstructured":"Assanatham M, Pattanaprateep O, Chuasuwan A, Vareesangthip K, Supasyndh O, Lumpaopong A et al. Economic evaluation of peritoneal Dialysis and Hemodialysis in Thai population with End-stage kidney disease. BMC Health Serv Res. 2022;22(1).","DOI":"10.1186\/s12913-022-08827-0"},{"issue":"1","key":"669_CR83","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.vhri.2013.02.003","volume":"2","author":"Y Onishi","year":"2013","unstructured":"Onishi Y, Hinotsu S, Nakao YM, Urushihara H, Kawakami K. Economic evaluation of Pravastatin for primary prevention of coronary artery disease based on risk prediction from JALS-ECC in Japan. Value Health Reg Issues. 2013;2(1):5\u201312.","journal-title":"Value Health Reg Issues"},{"issue":"1","key":"669_CR84","first-page":"23","volume":"40","author":"J Vongsaengnak","year":"2024","unstructured":"Vongsaengnak J, Tiamkao S. Cost of treatment for In-patient with acute stroke. Thai J Neurol. 2024;40(1):23\u201333.","journal-title":"Thai J Neurol"},{"key":"669_CR85","doi-asserted-by":"crossref","unstructured":"Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oup Oxford; 2006.","DOI":"10.1093\/oso\/9780198526629.001.0001"},{"issue":"9","key":"669_CR86","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1097\/01.hjh.0000174971.64589.39","volume":"23","author":"W Li","year":"2005","unstructured":"Li W, Liu LS, Puente JG, Li YS, Jiang XJ, Jin SG, et al. Hypertension and health-related quality of life: an epidemiological study in patients attending hospital clinics in China. J Hypertens. 2005;23(9):1667\u201376.","journal-title":"J Hypertens"},{"issue":"5","key":"669_CR87","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1177\/10105395211014650","volume":"33","author":"Z Zhu","year":"2021","unstructured":"Zhu Z, Yan W, Wang X, Hu D, Zhu Y, Chen J, Physical Activity. Blood pressure control, and Health-Related quality of life among hypertensive individuals: A Cross-Sectional study in Jiangsu province, China. Asia Pac J Public Health. 2021;33(5):539\u201346.","journal-title":"Asia Pac J Public Health"},{"issue":"6","key":"669_CR88","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1253\/circj.CJ-15-0150","volume":"79","author":"K Kario","year":"2015","unstructured":"Kario K, Ogawa H, Okumura K, Okura T, Saito S, Ueno T, et al. SYMPLICITY HTN-Japan - First randomized controlled trial of Catheter-Based renal denervation in Asian patients. Circ J. 2015;79(6):1222\u20139.","journal-title":"Circ J"},{"key":"669_CR89","doi-asserted-by":"crossref","unstructured":"Thavorncharoensap M, Teerawattananon Y, Natanant S, Kulpeng W, Yothasamut J, Werayingyong P. Estimating the willingness to pay for a quality-adjusted life year in Thailand:does the context of health gain matter? ClinicoEconomics and outcomes research: CEOR. 2013;5:29\u201336.","DOI":"10.2147\/CEOR.S38062"},{"issue":"1","key":"669_CR90","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jval.2019.10.005","volume":"23","author":"M Hasegawa","year":"2020","unstructured":"Hasegawa M, Komoto S, Shiroiwa T, Fukuda T. Formal implementation of Cost-Effectiveness evaluations in japan: A unique health technology assessment system. Value Health. 2020;23(1):43\u201351.","journal-title":"Value Health"},{"issue":"3","key":"669_CR91","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1161\/01.STR.0000056171.55342.FF","volume":"34","author":"Y Yoneda","year":"2003","unstructured":"Yoneda Y, Uehara T, Yamasaki H, Kita Y, Tabuchi M, Mori E. Hospital-based study of the care and cost of acute ischemic stroke in Japan. Stroke. 2003;34(3):718\u201324.","journal-title":"Stroke"},{"key":"669_CR92","doi-asserted-by":"crossref","unstructured":"Li Q, Fan X, Jian W. Impact of Diagnosis-Related-Group (DRG) payment on variation in hospitalization expenditure: evidence from China. BMC Health Serv Res. 2023;23(1).","DOI":"10.1186\/s12913-023-09686-z"},{"issue":"6","key":"669_CR93","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1586\/14737167.2013.847367","volume":"13","author":"Z Kalo","year":"2013","unstructured":"Kalo Z, Annemans L, Garrison LP. Differential pricing of new pharmaceuticals in lower income European countries. Expert Rev PharmacoEcon Outcomes Res. 2013;13(6):735\u201341.","journal-title":"Expert Rev PharmacoEcon Outcomes Res"},{"issue":"1","key":"669_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0168-8510(01)00151-8","volume":"58","author":"EP Slade","year":"2001","unstructured":"Slade EP, Anderson GF. The relationship between per capita income and diffusion of medical technologies. Health Policy. 2001;58(1):1\u201314.","journal-title":"Health Policy"},{"key":"669_CR95","doi-asserted-by":"crossref","unstructured":"Husain MJ, Datta BK, Kostova D, Joseph KT, Asma S, Richter P et al. Access to cardiovascular disease and hypertension medicines in developing countries: an analysis of essential medicine lists, price, availability, and affordability. J Am Heart Association. 2020;9(9).","DOI":"10.1161\/JAHA.119.015302"},{"issue":"1","key":"669_CR96","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.biotechadv.2005.06.004","volume":"24","author":"LA Salicrup","year":"2006","unstructured":"Salicrup LA, Fedorkov\u00e1 L. Challenges and opportunities for enhancing biotechnology and technology transfer in developing countries. Biotechnol Adv. 2006;24(1):69\u201379.","journal-title":"Biotechnol Adv"},{"key":"669_CR97","doi-asserted-by":"crossref","unstructured":"Taylor RS, Bentley A, Metcalfe K, Lobo MD, Kirtane AJ, Azizi M et al. Cost Effectiveness of Endovascular Ultrasound Renal Denervation in Patients with Resistant Hypertension. Pharmacoeconomics-Open. 2024.","DOI":"10.1007\/s41669-024-00472-z"},{"issue":"2","key":"669_CR98","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/03007995.2018.1491149","volume":"35","author":"S Irawati","year":"2019","unstructured":"Irawati S, Wasir R, Floriaan Schmidt A, Islam A, Feenstra T, Buskens E, et al. Long-term incidence and risk factors of cardiovascular events in Asian populations: systematic review and meta-analysis of population-based cohort studies. Curr Med Res Opin. 2019;35(2):291\u20139.","journal-title":"Curr Med Res Opin"}],"container-title":["Health Economics Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-025-00669-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13561-025-00669-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-025-00669-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T03:36:27Z","timestamp":1757388987000},"score":1,"resource":{"primary":{"URL":"https:\/\/healtheconomicsreview.biomedcentral.com\/articles\/10.1186\/s13561-025-00669-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["669"],"URL":"https:\/\/doi.org\/10.1186\/s13561-025-00669-w","relation":{},"ISSN":["2191-1991"],"issn-type":[{"value":"2191-1991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"assertion":[{"value":"10 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Funding from Shanghai Golden Leaf MedTech Company Limited for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years. no other relationships or activities that could appear to have influenced the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}